drugset / Trial / NCT00938912

An Open-Label Study to Determine Safety , Tolerability, and Efficacy of Oral Lacosamide in Children With Epilepsy

NCT00938912

Phase 2 Completed 366 enrolled UCB BIOSCIENCES, Inc.
NaSingle-groupOpen-labelTreatment

Summary

SP848 is an open-label study to evaluate long-term safety, tolerability, and efficacy in children with epilepsy treated with Lacosamide (LCM) oral solution (syrup) or LCM tablets as adjunctive therapy.

Timeline

Start
2009-12-09
Primary completion
2021-05-18
Completion
2021-05-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Lacosamide Other / unclassified 2 mg/kg Oral
Subject Lacosamide Other / unclassified 12 mg/kg Oral
Subject Lacosamide Other / unclassified 100 mg Oral
Subject Lacosamide Other / unclassified 600 mg Oral

Indications